Temozolomide + Thalidomide

From OncoWiki
Jump to: navigation, search

Indication

Metastatic cancer

  • Temozolomide (Temodar) 75 mg/m2 po qd x 6 wks every 8 wks
  • Thalidomide (Thalomid) 100-400 mg po qd
  • Thalidomide is classified as an immunomodulatory agent, and an antiangiogenic agent.

References

Hwu WJ et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 2003; 21:3351